engleski

Diagnostic utility of tumor marker CYFRA 21-1 in single pulmonary nodules

Lung cancer is ofen asymptomatic in the early stage. Later symptoms including cough, weight loss, chest pain and haemopthysis ofter reflect increased tumour size. Single pulmonary nodules (SPNs) represent a challenge in pulmonary diagnostics. Due to their frequent unsuitability for transbronchial biopsy, the final diagnosis is often postoponed. The aim was to assess the contribution to earlier diagnosis of lung cancer in patients with clinically non-verified single pulmonary nodules by means of measurement of serum level of tumor marker CYFRA 21-1. The saple consists of 431 patients with clinically uncharacterized SPNs at the time of primary diagnosis. When final diagnosis has been made, all the patients underwent surgical treatment. Data were analyzed according to pathohistological diagnosis obtained after surgery. Serum level of CYFRA 21-1 has been measured two times during the time of diagnosis using electrochemiluminescence imunoassay (Roche Diagnostics). Statistically significant increase of sensitivity according to preliminary cut-off value between two measurements was seen only in adenocarcinoma and squamous cell carcinoma. Other groups like pulmonary metastases, Hodgkin's disease, benign lung lesions and neuroendocrine tumors have not exhibited a significant increase of values. The dynamics between measurements separated primary non-small cell lung cancer (NSCLC) from other groups (p<0.0001). In conclusion, measurement of serum level of CYFRA 21-1 at the time of primary diagnosis of single pulmonary nodules can be the early parameter of recognition of NSCLC before standard diagnostic techniques. Also, CYFRA 21-1 can contribute to differential diagnosis by separation of primary NSCLC from metastatic tumors, benign lesions, malignant non-pulmonary disease and neuroendocrine tumors.

CYFRA 21-1 ; lung cancer ; single pulmonary nodule

nije evidentirano